Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

A collection of videos, study abstracts, and other resources all focused on disparities in obesity. Obesity is independently ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...

Multimodal AOMs were associated with the highest preoperative weight loss among patients with high BMI undergoing bariatric surgery.

The most frustrating part about MASLD is that this serious illness can be reversed with early identification and treatment.

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

Novo has enjoyed a tremendous windfall of $46 billion in net profit since mid-2021, when Wegovy became the first highly effective obesity treatment approved in the United States ...

From dermatitis to acne, know skin conditions that can be triggered by obesity. Doctor shares prevention tips to follow.